PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITGXY5KSzVyPUCuNFIzPzZizszN M1vaWHNCVkeHUh?=
CHP-212 NUXBTIFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XZNmlEPTB;MD6wNlg5PSEQvF2= M4rnWnNCVkeHUh?=
EoL-1-cell NWT2UItTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMESxOVIh|ryP MXzTRW5ITVJ?
DU-4475 NVPRdYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT2eHM3UUN3ME2wMlA4PTl7IN88US=> M3rUfXNCVkeHUh?=
MMAC-SF NGn5Z|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm0TWM2OD1yLkGwPVc1KM7:TR?= Mn\NV2FPT0WU
AGS M2jtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3QUlY3UUN3ME2wMlEyPzF|IN88US=> NXG2SpEyW0GQR1XS
M14 NE\HeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33VXGlEPTB;MD6xOVQ3QCEQvF2= M3vjUXNCVkeHUh?=
CP50-MEL-B NFraTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnnTWM2OD1yLkG3NlU1KM7:TR?= NWPmNY54W0GQR1XS
C32 NUKzdWZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS1TWM2OD1yLkG5NFczKM7:TR?= NWq1UlNFW0GQR1XS
KMOE-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMUm3PVUh|ryP Mni0V2FPT0WU
A101D MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO1VnpKSzVyPUCuNlE1KM7:TR?= NGP1T2ZUSU6JRWK=
KM12 NWnSeY45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[2O2tKSzVyPUCuNlQxPTdizszN Mne3V2FPT0WU
HSC-4 NVPOclJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13UfGlEPTB;MD6yOFM6PSEQvF2= M1nY[3NCVkeHUh?=
NOMO-1 M2XteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXtTWM2OD1yLkK1O|QzKM7:TR?= MmX6V2FPT0WU
MZ7-mel NWHOR2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnzTZNzUUN3ME2wMlI3OzRizszN M3TvV3NCVkeHUh?=
ACN NIXNOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3hTWM2OD1yLkK2O|M4KM7:TR?= MnXUV2FPT0WU
MEL-HO MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL1[FdJUUN3ME2wMlI4PjV{IN88US=> NXizZZVwW0GQR1XS
BHT-101 NGi0W2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu1WGFKSzVyPUCuNlg3ODZizszN MkLkV2FPT0WU
SK-MEL-28 NXTySZFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HqO2lEPTB;MD6zNFQxQSEQvF2= MnPvV2FPT0WU
KG-1 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;1VHlKSzVyPUCuN|A3PjhizszN MoTDV2FPT0WU
COLO-679 M{DpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTETWM2OD1yLkOyO|Ih|ryP MVzTRW5ITVJ?
SK-MEL-24 NXG5fI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvYTWM2OD1yLkOyPFE{KM7:TR?= NWD3bYxZW0GQR1XS
G-361 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorCTWM2OD1yLkO2O|k2KM7:TR?= NXrxSJZsW0GQR1XS
KY821 NWPicnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXwbpFrUUN3ME2wMlM4QTFizszN MVXTRW5ITVJ?
KASUMI-1 M3XUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL6VWY5UUN3ME2wMlM6QSEQvF2= M4L5WnNCVkeHUh?=
HL-60 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zw[GlEPTB;MD60NVExPyEQvF2= NGDXTZpUSU6JRWK=
K5 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzuPFhvUUN3ME2wMlQ{OTF5IN88US=> M4PncHNCVkeHUh?=
KU812 NVzjVIh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwNEWyPVkh|ryP M{PIN3NCVkeHUh?=
SH-4 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\jW2NKSzVyPUCuOFYzPTZizszN NHKxN2JUSU6JRWK=
HTC-C3 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC1TWM2OD1yLkS2OVMyKM7:TR?= MX3TRW5ITVJ?
CP66-MEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHWcXJKSzVyPUCuOFg5ODlizszN MYjTRW5ITVJ?
WM-115 NWjmdJN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwNEmyOVch|ryP NV\zSXBKW0GQR1XS
A2780 MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonJTWM2OD1yLkS5PFI{KM7:TR?= M1HSd3NCVkeHUh?=
P12-ICHIKAWA Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PWdmlEPTB;MD62NVIzOSEQvF2= NIrPZ5RUSU6JRWK=
HMV-II NWL4S|NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn6ZXFKSzVyPUCuOlQ1PjVizszN NFHYO3JUSU6JRWK=
HT-144 NFXyZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDKTWM2OD1yLk[0OlU4KM7:TR?= Mn7qV2FPT0WU
LB2518-MEL MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW2R2lKSzVyPUCuO|E3OzJizszN NX;WcpFDW0GQR1XS
NCI-SNU-1 M4XwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\6UHRKSzVyPUCuO|U1OzNizszN NX\HXVVDW0GQR1XS
C2BBe1 M1q4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz3TWM2OD1yLkixNFI{KM7:TR?= MnzqV2FPT0WU
PSN1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHGTWM2OD1yLkm2NVk3KM7:TR?= M3SxUnNCVkeHUh?=
UACC-257 M1H1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ze3pIUUN3ME2wMlk3PDd|IN88US=> NWLldJhGW0GQR1XS
RVH-421 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrQVZdzUUN3ME2wMlk4OThizszN MVXTRW5ITVJ?
GP5d M3PDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vGUGlEPTB;MD65PFMxQCEQvF2= NIL3dIZUSU6JRWK=
TYK-nu NHfMN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;5TWM2OD1zLkCzNVczKM7:TR?= NHrOXZZUSU6JRWK=
SK-N-AS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPreFBKSzVyPUGuNFc6PDdizszN MkX2V2FPT0WU
SW620 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LnemlEPTB;MT6xN|U{PCEQvF2= MnHjV2FPT0WU
HuP-T4 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwMUizOVkh|ryP MkLxV2FPT0WU
A549 NVTpdlNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMUm1O|Yh|ryP MXLTRW5ITVJ?
Mewo M2nCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXFTWM2OD1zLkKwNlc3KM7:TR?= NIHmV|hUSU6JRWK=
ONS-76 M1HDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPRTZV3UUN3ME2xMlIzODR7IN88US=> NFy5[3hUSU6JRWK=
SK-MEL-1 NX:4VYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHjN|dKSzVyPUGuNlM1OTlizszN NIT2c3pUSU6JRWK=
RCM-1 NYiwRo9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXyVJFzUUN3ME2xMlI1ODR5IN88US=> MXPTRW5ITVJ?
H-EMC-SS M12zcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMkm2NFgh|ryP M1z5S3NCVkeHUh?=
NCI-H2291 M2S3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PBZ2lEPTB;MT6zNlU{PiEQvF2= M3Gw[HNCVkeHUh?=
SW1463 NGP4UIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P1NGlEPTB;MT6zN|czOSEQvF2= MYjTRW5ITVJ?
LS-411N NVn5R4ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2joOWlEPTB;MT60NFUyPyEQvF2= MV\TRW5ITVJ?
BV-173 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHiR49NUUN3ME2xMlQ1ODF3IN88US=> NV3YbJFjW0GQR1XS
LS-513 NFzESHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPTTWM2OD1zLkS1NVkzKM7:TR?= M3vDOXNCVkeHUh?=
LoVo NFPMfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwNE[zPVkh|ryP NH3kN2hUSU6JRWK=
HO-1-N-1 NGjVdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLOTnFzUUN3ME2xMlUyPjN2IN88US=> NIPuTFdUSU6JRWK=
ML-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfOe49KSzVyPUGuOVI5PjhizszN MYXTRW5ITVJ?
NCI-H1437 NWG1R2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7CTWM2OD1zLkW1Nlc2KM7:TR?= NEDrbmhUSU6JRWK=
SW1116 M1jRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwNU[zPVgh|ryP NXf2cI9bW0GQR1XS
A4-Fuk MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f4emlEPTB;MT61O|A1PSEQvF2= MnrOV2FPT0WU
HD-MY-Z MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq5UYtMUUN3ME2xMlU4Ozd4IN88US=> M2fSXXNCVkeHUh?=
SK-MEL-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3joeWlEPTB;MT61O|Q2QSEQvF2= M4D0dXNCVkeHUh?=
RT-112 NWDFfGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq3SldrUUN3ME2xMlU5QTV{IN88US=> MXXTRW5ITVJ?
COLO-829 NVfleW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwNkKyN|Ih|ryP NFr1R4hUSU6JRWK=
OVCAR-5 NUXE[4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvTTWM2OD1zLke3Olg4KM7:TR?= NY\PW|dbW0GQR1XS
NB69 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwN{i0Olkh|ryP M4ThbXNCVkeHUh?=
NCI-H292 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwOE[2PVkh|ryP MVXTRW5ITVJ?
LOXIMVI MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwOEm0Nlch|ryP NFvZfIRUSU6JRWK=
BPH-1 NV2xOXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\3TWM2OD1zLki5OVkyKM7:TR?= MlHqV2FPT0WU
A375 NGDwTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwOEm3NVQh|ryP NXj4XnRXW0GQR1XS
LCLC-97TM1 M3;ZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwOUKyOVYh|ryP MYjTRW5ITVJ?
RXF393 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ryfWlEPTB;MT65O|g5PyEQvF2= NHzjV3FUSU6JRWK=
HCC70 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITndI5KSzVyPUKuNFI1OjZizszN MYHTRW5ITVJ?
EM-2 NIezclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LQWmlEPTB;Mj6wO|E6QCEQvF2= MmP4V2FPT0WU
MZ2-MEL NXjCWZVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwMUGxNlch|ryP MmHrV2FPT0WU
HN NHHBVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HYWWlEPTB;Mj6xOlI4QCEQvF2= Ml\VV2FPT0WU
A2058 NEjVe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG5VGFtUUN3ME2yMlE6Ojd7IN88US=> NV;Lb4RTW0GQR1XS
NB7 NGX1OJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD2TWM2OD1{LkO0NFg3KM7:TR?= NHu1eFBUSU6JRWK=
DOK MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\4flhKSzVyPUKuN|U4PzNizszN M2XhSnNCVkeHUh?=
CAL-27 NELHbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr0THNKSzVyPUKuN|kzOzZizszN MnfBV2FPT0WU
BB65-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T2d2lEPTB;Mj60NFY4PCEQvF2= NXX6d3NyW0GQR1XS
RD MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXFN49KSzVyPUKuOFQ4OjNizszN MYfTRW5ITVJ?
KNS-62 NUWxT5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D2cGlEPTB;Mj61NVE3PCEQvF2= MoTLV2FPT0WU
EW-13 NYHERnRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{mxdWlEPTB;Mj61OlM{QSEQvF2= NHzIdYFUSU6JRWK=
DB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwNUi3PFgh|ryP MoL2V2FPT0WU
HCC2218 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnLeXRCUUN3ME2yMlY1Pzd6IN88US=> Mnz5V2FPT0WU
L-363 M1S5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJwN{SzO{DPxE1? MXfTRW5ITVJ?
CHL-1 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3YUlRKSzVyPUKuPFA4QDVizszN MUHTRW5ITVJ?
BFTC-905 M4fIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rQdWlEPTB;Mj64NlU{KM7:TR?= M{fERXNCVkeHUh?=
HCE-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYixboR7UUN3ME2yMlg{OjZ2IN88US=> MlPFV2FPT0WU
COLO-792 NWXCcJFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzLTWM2OD1{Lki0NFI4KM7:TR?= MkXZV2FPT0WU
LB2241-RCC M4fNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fNOmlEPTB;Mj64OVg6OyEQvF2= M1v0enNCVkeHUh?=
CAL-39 M1vJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnFT3hpUUN3ME2yMlg6QTl7IN88US=> MlTwV2FPT0WU
T-24 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwOUGxNVIh|ryP MYXTRW5ITVJ?
NCI-H727 M{G1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHSTWM2OD1{LkmxO|k3KM7:TR?= NVvtO|dWW0GQR1XS
Ca9-22 NEHhZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLxOIQ3UUN3ME2yMlk4OjV3IN88US=> MkXhV2FPT0WU
MIA-PaCa-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXub3NKSzVyPUOuNFA4QDFizszN MWDTRW5ITVJ?
HT-1080 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;FNI5kUUN3ME2zMlAyQTl5IN88US=> NHi3W4RUSU6JRWK=
D-423MG NGHuVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPfGlEPTB;Mz6wO|c2OyEQvF2= Ml;LV2FPT0WU
LAMA-84 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMUO1PEDPxE1? MYnTRW5ITVJ?
SW780 NHX1UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rY[2lEPTB;Mz6xOFIzQSEQvF2= MVnTRW5ITVJ?
KU-19-19 NF\pVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;3PGlEPTB;Mz6xO|A{PCEQvF2= MmO0V2FPT0WU
COLO-741 NELXfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3wTWM2OD1|LkG4Olc{KM7:TR?= MkHyV2FPT0WU
HSC-3 NU\YbFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{THcGlEPTB;Mz6yN|E2OSEQvF2= M{DyN3NCVkeHUh?=
SN12C M4rpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFew[FdKSzVyPUOuNlQ4ODFizszN MW\TRW5ITVJ?
786-0 NVrpblRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DWb2lEPTB;Mz6yO|I1OyEQvF2= M3zhR3NCVkeHUh?=
GAK M{LxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNwM{K1OlEh|ryP NEHYR5JUSU6JRWK=
PANC-03-27 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\GOmlEPTB;Mz6zOVA1PSEQvF2= M1foZXNCVkeHUh?=
CTB-1 NUXqe5VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnHfJJKSzVyPUOuOFcxPDdizszN NYPZ[GFtW0GQR1XS
A427 M3i4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fPcGlEPTB;Mz61PVU2PiEQvF2= NHv5XpFUSU6JRWK=
EGI-1 NEHET2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfFTWM2OD1|Lk[wOVg{KM7:TR?= MU\TRW5ITVJ?
U-2-OS NIDMSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqyTWM2OD1|Lk[3NlU3KM7:TR?= NETVWYdUSU6JRWK=
NCI-SNU-5 NGHjSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrLTWM2OD1|Lk[3O|Mh|ryP M2jFTXNCVkeHUh?=
SK-LU-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNwNki3PVgh|ryP MWLTRW5ITVJ?
697 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHrTWM2OD1|Lk[5OlA{KM7:TR?= MnTJV2FPT0WU
HPAF-II M4DLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;WeGlEPTB;Mz63OVQ6KM7:TR?= MVjTRW5ITVJ?
NCI-H2087 M1PzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwOES2O|Ih|ryP MVTTRW5ITVJ?
SK-MEL-3 NEnMRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrDfWVKSzVyPUOuPFUyPTRizszN MkCxV2FPT0WU
CGTH-W-1 NVPpe4d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zleWlEPTB;Mz64OVczPSEQvF2= MUPTRW5ITVJ?
8505C MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHkbW9lUUN3ME2zMlkxODd6IN88US=> MUDTRW5ITVJ?
GAMG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S3SGlEPTB;ND6wNlM4PyEQvF2= MmTHV2FPT0WU
SW626 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTRwMES0PEDPxE1? MVTTRW5ITVJ?
CAL-62 NYDJW4NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS1b4hKSzVyPUSuNFc1OyEQvF2= MlzMV2FPT0WU
MHH-PREB-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f5cGlEPTB;ND6xNlEyOSEQvF2= MVjTRW5ITVJ?
RPMI-7951 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\USIRKSzVyPUSuNlU2QDlizszN NGSyUWtUSU6JRWK=
HOP-92 M4HGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;xUHdKSzVyPUSuNlU3PyEQvF2= M3;UZ3NCVkeHUh?=
MDA-MB-231 NIn2d4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPMTWM2OD12LkK5NlI{KM7:TR?= MkHhV2FPT0WU
LAN-6 NYHvWo5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojtTWM2OD12LkOxOlM4KM7:TR?= NWnRfndMW0GQR1XS
ALL-PO M37RO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXqbXpKSzVyPUSuN|YyPTZizszN M1PyR3NCVkeHUh?=
HH NH72VoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fBfGlEPTB;ND60NVU6PyEQvF2= MlfUV2FPT0WU
IGROV-1 NFjSWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULLUGlbUUN3ME20MlQ2OTdzIN88US=> NITseoZUSU6JRWK=
NCI-H358 M3nzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\pUJZKSzVyPUSuOFU{QDVizszN MX3TRW5ITVJ?
NB5 M{HoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7VTWM2OD12Lk[wN|Y6KM7:TR?= NGri[|dUSU6JRWK=
NCI-H747 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwNki4NFch|ryP NW\nU3lvW0GQR1XS
NH-12 NX7YcllGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRwN{G2NlUh|ryP M{PKfHNCVkeHUh?=
LB1047-RCC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzFRY41UUN3ME20Mlc{QDF3IN88US=> Ml;6V2FPT0WU
EFO-27 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDNbFAxUUN3ME20Mlc5PjZ5IN88US=> MkX6V2FPT0WU
EPLC-272H NHTNR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLtTWM2OD12Lkm5OlY6KM7:TR?= M13UV3NCVkeHUh?=
CAL-54 M3P6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;xV2JDUUN3ME21MlAzPjl3IN88US=> NWC1W3dGW0GQR1XS
H4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPofXVKSzVyPUWuNFQzPTVizszN MVfTRW5ITVJ?
MOLT-13 NGTvdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK4ZlhKSzVyPUWuNFY4PzZizszN NGD2RVZUSU6JRWK=
CAL-33 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TSemlEPTB;NT6xNlMyPyEQvF2= NHXP[21USU6JRWK=
23132-87 M2P6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPBTWM2OD13LkG2PFczKM7:TR?= M4\QR3NCVkeHUh?=
UM-UC-3 NFizZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVwMUiwOFch|ryP MmSxV2FPT0WU
HuH-7 M1LpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTVwMkexOFch|ryP M4X4dHNCVkeHUh?=
BCPAP NHKxSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\wfGpSUUN3ME21MlMzQTZ7IN88US=> NX\ERpFUW0GQR1XS
AsPC-1 M{HJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW0dndHUUN3ME21MlM3PzZ|IN88US=> MYPTRW5ITVJ?
NCI-H1155 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\MT2tLUUN3ME21MlQxODVzIN88US=> MoTEV2FPT0WU
GT3TKB NWLP[GlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37iV2lEPTB;NT60OlU6QCEQvF2= MXrTRW5ITVJ?
HCC2998 M33vTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq0TWM2OD13LkS5NVA6KM7:TR?= MkLPV2FPT0WU
NUGC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O1XmlEPTB;NT60PVMxOiEQvF2= MXLTRW5ITVJ?
Hs-578-T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnGNZBKSzVyPUWuOVM4QTRizszN M2PYb3NCVkeHUh?=
FADU MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTVwNUW3NlYh|ryP NUTqbpV3W0GQR1XS
NBsusSR Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[3UodKSzVyPUWuOVcyPTVizszN NXPPfJhOW0GQR1XS
ME-180 NV7ieG1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXMTWM2OD13LkW4NFkzKM7:TR?= MoDzV2FPT0WU
SW1710 NUL6UWZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnwNVVKSzVyPUWuOlE3PTRizszN MmrLV2FPT0WU
HuP-T3 M{WzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH5TWM2OD13Lk[yNFI6KM7:TR?= NVnxbmk2W0GQR1XS
HOS NYO3OplKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfTTWM2OD13Lk[yPVI{KM7:TR?= MYrTRW5ITVJ?
PA-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfGc45KSzVyPUWuOlQzPjVizszN MnfCV2FPT0WU
LU-99A MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\rTWM2OD13Lk[2OFUyKM7:TR?= MlrnV2FPT0WU
RS4-11 M2Lw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID1bFdKSzVyPUWuOlY4PzVizszN MofwV2FPT0WU
TE-8 NGXr[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW5TJNKSzVyPUWuOlg2OzdizszN MWjTRW5ITVJ?
RERF-LC-MS Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwNki4NFMh|ryP NYjtd45jW0GQR1XS
MEL-JUSO MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XzNGlEPTB;NT63N|c5KM7:TR?= NGeyZZhUSU6JRWK=
SK-MES-1 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCwZ5FVUUN3ME21Mlg{PTJ6IN88US=> M2LPPXNCVkeHUh?=
D-263MG MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTWfYdlUUN3ME21Mlg5OzVzIN88US=> Mle4V2FPT0WU
NB10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vGPWlEPTB;NT64PVQ3KM7:TR?= MV3TRW5ITVJ?
SK-HEP-1 NH7oV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTVwOUO0O|Eh|ryP M3TPcHNCVkeHUh?=
HT-29 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP6TWM2OD13Lkm4NVE5KM7:TR?= MVHTRW5ITVJ?
KYSE-140 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrOTWM2OD14LkCyNVgzKM7:TR?= MVTTRW5ITVJ?
NCI-H1666 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\0TWM2OD14LkC4OFYyKM7:TR?= Mn:yV2FPT0WU
NCI-H1304 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnTSG5KSzVyPU[uNVk6PCEQvF2= M3jiZXNCVkeHUh?=
RPMI-8866 NHO5XYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHMTWM2OD14LkKxN|E{KM7:TR?= MYrTRW5ITVJ?
MV-4-11 NWfOS3ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzZTVRSUUN3ME22MlI{OTl7IN88US=> NYfXdGNxW0GQR1XS
A431 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPiTWM2OD14LkK0Nlk3KM7:TR?= NFe0UWZUSU6JRWK=
PANC-10-05 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LDXGlEPTB;Nj6yPFM3OyEQvF2= Mnm3V2FPT0WU
TK10 NEC4XI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWraXYpIUUN3ME22MlMzPjB2IN88US=> NXvOPWl6W0GQR1XS
NCI-H1975 M3G2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[wTWM2OD14LkS3NlE2KM7:TR?= NXTw[XZiW0GQR1XS
A172 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLBcXdYUUN3ME22MlQ6OTd4IN88US=> NYPBUGJUW0GQR1XS
D-566MG Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvZWWVQUUN3ME22MlU1OzB|IN88US=> NGfOd3hUSU6JRWK=
NCI-H2122 MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrPTWM2OD14Lk[xOVI5KM7:TR?= NEHZXINUSU6JRWK=
COR-L105 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTZwNkWyO|Uh|ryP NVLxWIx5W0GQR1XS
AN3-CA M1vnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DwS2lEPTB;Nj62PFY1OSEQvF2= NFfqV5lUSU6JRWK=
Calu-6 NIHyOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LOcmlEPTB;Nj63PVY6QCEQvF2= MYrTRW5ITVJ?
HCT-116 M4W1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGwOmFUUUN3ME22MlgyOjZ2IN88US=> M1jRd3NCVkeHUh?=
MHH-NB-11 NWPCT29yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HER2lEPTB;Nj64OVAxOiEQvF2= MlLjV2FPT0WU
MFE-280 NVfWTHdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTZwOEW5PFMh|ryP M2PieHNCVkeHUh?=
SW1088 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPkU5NXUUN3ME22MlkyQTF|IN88US=> NEPTbXhUSU6JRWK=
SW48 NX\KbHhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPqd4tKSzVyPU[uPVQ2OSEQvF2= MVrTRW5ITVJ?
HuCCT1 NI\HWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfFTWM2OD15LkCxNFM4KM7:TR?= Mn;vV2FPT0WU
ACHN MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnWTWM2OD15LkCyPVQ{KM7:TR?= MkTpV2FPT0WU
8305C MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XQe2lEPTB;Nz6wPVk6PSEQvF2= MlzWV2FPT0WU
DoTc2-4510 M4nZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXLUVNTUUN3ME23MlEzOTVizszN MX3TRW5ITVJ?
COR-L23 M{jmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrPTWM2OD15LkK0OFIh|ryP MoDjV2FPT0WU
SK-MEL-30 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\CT2lEPTB;Nz6yOVA5OyEQvF2= MYTTRW5ITVJ?
BE-13 NUTTZ2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTdwM{O4N|Qh|ryP NFn3OmhUSU6JRWK=
GR-ST NFPGbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXDW2p3UUN3ME23MlQxOTd2IN88US=> M{jRNXNCVkeHUh?=
LU-135 NEHiRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTdwNUW5N|kh|ryP NVywWopJW0GQR1XS
U-266 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTdwNU[yPFYh|ryP MnnBV2FPT0WU
NCI-H1355 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DjT2lEPTB;Nz61PFY{PSEQvF2= NIXLVIhUSU6JRWK=
NB14 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHzTWM2OD15Lk[2OlQzKM7:TR?= NHL0PFFUSU6JRWK=
SCC-25 NHTTbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfyR21KSzVyPUeuO|A6KM7:TR?= MoHzV2FPT0WU
COLO-678 NWrMXVhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP1TWM2OD15LkexNFc3KM7:TR?= MofFV2FPT0WU
TGBC1TKB MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvwbFV4UUN3ME23Mlg6Ozl6IN88US=> M3zkOXNCVkeHUh?=
IST-MEL1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRThwMEC0NFYh|ryP MV3TRW5ITVJ?
ECC10 NYPvdpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRThwMEOzPVUh|ryP MmTFV2FPT0WU
EW-16 NGKxT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRThwMEi0OFUh|ryP MXvTRW5ITVJ?
DOHH-2 NVfCSmN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHCTWM2OD16LkKwNFk2KM7:TR?= NGj3VXRUSU6JRWK=
NCI-H1581 M4C0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjDbGJnUUN3ME24MlI3OzJ|IN88US=> NV:yXGZVW0GQR1XS
TE-5 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfEZpdKSzVyPUiuOFI1OjlizszN NHO4U4dUSU6JRWK=
CAKI-1 NUPMZ5luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC4U4pKSzVyPUiuOVczOjJizszN MoD3V2FPT0WU
A673 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTvcGpKSzVyPUiuOlMzODJizszN NFWxRohUSU6JRWK=
CAL-12T MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X1cmlEPTB;OD62OVc2OyEQvF2= MmT3V2FPT0WU
DBTRG-05MG M4PVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRThwN{S4OVkh|ryP NFvDN4ZUSU6JRWK=
SK-N-FI NXrGe2tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH4blFmUUN3ME24MlgyOzd7IN88US=> MVPTRW5ITVJ?
K-562 M3ywdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vibmlEPTB;OD64N|k2PyEQvF2= NVHjN5dOW0GQR1XS
SBC-1 NHvuNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXybYpKSzVyPUiuPFY3PDVizszN M{\wcHNCVkeHUh?=
ES4 NX3uZYV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRThwOE[4PFQh|ryP MVPTRW5ITVJ?
MS-1 NULnTWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPpOXhKSzVyPUiuPFc2OTdizszN NFTNT4JUSU6JRWK=
RKO M3\iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OybGlEPTB;OD64PVA2PyEQvF2= NXPNVFF1W0GQR1XS
NCI-H1693 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K3cWlEPTB;OD65NlE4KM7:TR?= MXzTRW5ITVJ?
SW954 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXv[oxKSzVyPUiuPVY6PzhizszN MUfTRW5ITVJ?
SK-UT-1 MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\XOpZKSzVyPUiuPVc3QDNizszN MnLiV2FPT0WU
T98G MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DmfGlEPTB;OD65PVg1PiEQvF2= MWHTRW5ITVJ?
NCI-H2126 NUXB[os1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXofIVmUUN3ME25MlAxQDJ4IN88US=> M3TYOnNCVkeHUh?=
TE-12 M1;2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\1elIyUUN3ME25MlA{OzZ5IN88US=> M37OTHNCVkeHUh?=
DK-MG NW\CRmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfmTWM2OD17LkKxNVkyKM7:TR?= MYXTRW5ITVJ?
MEG-01 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULqZoJGUUN3ME25MlI1QTNzIN88US=> M1HRcXNCVkeHUh?=
HCC1937 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonaTWM2OD17LkK5NFkyKM7:TR?= NV:4dpUzW0GQR1XS
MKN45 NWe1VnJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXhT3hjUUN3ME25MlQ2ODZ3IN88US=> M{TWOHNCVkeHUh?=
NCI-H1792 M3jOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV60b2lxUUN3ME25MlQ2OjF7IN88US=> Ml;LV2FPT0WU
SW1417 NFzqdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHaZpJkUUN3ME25MlU3QDN5IN88US=> NY\jWlRuW0GQR1XS
639-V MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K4RmlEPTB;OT62OFM5QCEQvF2= NULzNGRMW0GQR1XS
P30-OHK MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTaNWlKSzVyPUmuOlU{OTZizszN NUfLNFRGW0GQR1XS
YKG-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTlwN{WwN|Mh|ryP NYXsbmJFW0GQR1XS
KGN Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfpOZlKSzVyPUmuPFM4QTVizszN MYrTRW5ITVJ?
MSTO-211H MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInkW4NKSzVyPUmuPVU2OjlizszN NFjncHpUSU6JRWK=
NCI-H1573 M1zo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13QWWlEPTB;MUCuNVU4PCEQvF2= NVjRcllKW0GQR1XS
NCI-H720 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnSfVRjUUN3ME2xNE4yQTh7IN88US=> NFjNeplUSU6JRWK=
KARPAS-45 NXPp[4ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvQTWM2OD1zMD6yO|k2KM7:TR?= MoXuV2FPT0WU
MDA-MB-175-VII NFLQeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFyLkS4JO69VQ>? M1jqenNCVkeHUh?=
SK-NEP-1 NHLj[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnudoNKSzVyPUGwMlQ6QDFizszN MYDTRW5ITVJ?
MKN28 NILSZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\XTYx7UUN3ME2xNE42OThizszN NWTxc5RHW0GQR1XS
KYSE-520 M1TxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPRTWM2OD1zMD61NkDPxE1? MWjTRW5ITVJ?
KE-37 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojFTWM2OD1zMD61NlczKM7:TR?= MlzxV2FPT0WU
VA-ES-BJ NGK4SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPsW45KSzVyPUGwMlU3PyEQvF2= M{PGb3NCVkeHUh?=
CCRF-CEM NHf3OHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXflc2ZxUUN3ME2xNE42Pjh2IN88US=> MoXwV2FPT0WU
GMS-10 NIS1OWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyLk[wPVQh|ryP NVTaZ4lRW0GQR1XS
NCI-H1623 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL0NYNHUUN3ME2xNE43Ozd7IN88US=> MVzTRW5ITVJ?
NEC8 NFjJ[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXhU3VKSzVyPUGwMlc4PzNizszN NVzHV|dsW0GQR1XS
MOLT-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnRTW82UUN3ME2xNE45OTF|IN88US=> NX7xXJFoW0GQR1XS
DJM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFzLkCzO|kh|ryP NInmWHlUSU6JRWK=
U251 NIT3e5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K1XmlEPTB;MUGuNFQzKM7:TR?= M2nCenNCVkeHUh?=
SBC-5 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjuUGlKSzVyPUGxMlE1PjdizszN Mnj0V2FPT0WU
SW756 NGXVWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFzLkKxOVQh|ryP MYTTRW5ITVJ?
KS-1 NEfvNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnzTWM2OD1zMT6yOlE6KM7:TR?= NFLWPGFUSU6JRWK=
SF295 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TSRWlEPTB;MUGuN|ExPCEQvF2= MmWzV2FPT0WU
YH-13 M4Hae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qx[WlEPTB;MUGuN|I3PyEQvF2= NIrGV|lUSU6JRWK=
SW837 M1OzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHLOopKSzVyPUGxMlM2ODZizszN Mmm2V2FPT0WU
KYSE-450 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfZdGlNUUN3ME2xNU41ODV5IN88US=> MnnSV2FPT0WU
KYSE-180 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFzLkS4NkDPxE1? MVjTRW5ITVJ?
S-117 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LPc2lEPTB;MUGuOFg6PiEQvF2= MmqwV2FPT0WU
KOSC-2 NUHhXHU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq1R2xKSzVyPUGxMlYzOjJizszN NUL0VY1MW0GQR1XS
KYSE-270 NIOxfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrmV4xKSzVyPUGxMlg4PDVizszN NXfvfXUzW0GQR1XS
D-336MG NGfBe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFzLkmwO|Uh|ryP NWjnVIRyW0GQR1XS
KALS-1 NYrhdYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqOFdKSzVyPUGyMlAxOTZizszN MojFV2FPT0WU
LB373-MEL-D MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3XcJpTUUN3ME2xNk4xPTN|IN88US=> MX7TRW5ITVJ?
HLE M3zFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\CTWM2OD1zMj6wOVg2KM7:TR?= M4Sxc3NCVkeHUh?=
SJSA-1 M3;Ge2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vWSWlEPTB;MUKuNFc{PSEQvF2= MlnWV2FPT0WU
SW1990 NHG0d|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF{LkC5NVEh|ryP M4fSV3NCVkeHUh?=
NOS-1 NH\IOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTnVGZ1UUN3ME2xNk4yOzV{IN88US=> MVLTRW5ITVJ?
GI-ME-N M{H4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF{LkKxOlMh|ryP M4K5[nNCVkeHUh?=
NCI-H1703 M2j5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjXU4tKSzVyPUGyMlI3OTZizszN M2LIbnNCVkeHUh?=
ES7 NGTxVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELCeZBKSzVyPUGyMlI4OjRizszN M1OzR3NCVkeHUh?=
KYSE-510 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHsfZpKUUN3ME2xNk42ODd7IN88US=> M1HGTXNCVkeHUh?=
BHY Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF{LkWzNFch|ryP NFfKUI1USU6JRWK=
TCCSUP NELCXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fYbGlEPTB;MUKuOVc2PyEQvF2= M3XoNXNCVkeHUh?=
HSC-2 NFq1N3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF{LkW5PVYh|ryP MnHiV2FPT0WU
BEN NWTzVYExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\5TWM2OD1zMj62NVQ{KM7:TR?= MYrTRW5ITVJ?
769-P MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvxS4FYUUN3ME2xNk44QTJ2IN88US=> NHXrSGNUSU6JRWK=
HT NF6ybVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF{LkizOFYh|ryP NEDHN|lUSU6JRWK=
LXF-289 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECzcHpKSzVyPUGyMlk2OzFizszN MVvTRW5ITVJ?
OVCAR-3 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjlcldKSzVyPUGyMlk2PjdizszN NI\Pd|dUSU6JRWK=
ATN-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljrTWM2OD1zMz6wNVg1KM7:TR?= NXjPXpRxW0GQR1XS
8-MG-BA NUfIRlRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXJXGFKSzVyPUGzMlA1PTVizszN M2LxfHNCVkeHUh?=
SW13 NX\pbWNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonvTWM2OD1zMz6xNVY2KM7:TR?= MnrXV2FPT0WU
NCI-H1092 M3jsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDibolKSzVyPUGzMlE3OiEQvF2= NGnmPWlUSU6JRWK=
OAW-42 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O2[WlEPTB;MUOuNVk{PyEQvF2= MkfCV2FPT0WU
NCI-H2452 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX34V5dKUUN3ME2xN{4zOTd3IN88US=> MUfTRW5ITVJ?
CAPAN-1 NI\1NGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF|LkW1NVQh|ryP M1HZRnNCVkeHUh?=
NCI-H2009 NIjOflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjNeodlUUN3ME2xN{42QTF7IN88US=> M2PGSHNCVkeHUh?=
SF268 M2raS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XEd2lEPTB;MUOuOlMzPiEQvF2= M1jUTnNCVkeHUh?=
GCIY M{\WSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXJfm1pUUN3ME2xN{43QTJ5IN88US=> NH;CT2pUSU6JRWK=
OS-RC-2 NEnpdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPyTWM2OD1zMz65OVAyKM7:TR?= NGXWWHJUSU6JRWK=
GCT NUjn[5I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljlTWM2OD1zMz65Olk4KM7:TR?= NX;vZldDW0GQR1XS
NB17 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnETWM2OD1zND6wPFUh|ryP NG\1XmhUSU6JRWK=
NCI-H2030 NWfiW5B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTWTWM2OD1zND6xOFY2KM7:TR?= MWXTRW5ITVJ?
HC-1 M3OzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm3W5JwUUN3ME2xOE4zODh5IN88US=> MlPFV2FPT0WU
QIMR-WIL NXnVfIk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vrRWlEPTB;MUSuN|QyOiEQvF2= NUjZRoZ7W0GQR1XS
Capan-2 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;KTWM2OD1zND6zO|E1KM7:TR?= NYnmNlhXW0GQR1XS
BALL-1 NVjFVGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjOc3dDUUN3ME2xOE41PjZ3IN88US=> MYnTRW5ITVJ?
LS-1034 M1K4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPNUFZOUUN3ME2xOE43OTV{IN88US=> NV[xW3dGW0GQR1XS
U-118-MG NYjYTHpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj4UYNKSzVyPUG0MlY{OSEQvF2= MnLWV2FPT0WU
NCI-H630 NYXuZ4hTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfrTWM2OD1zND62OVY5KM7:TR?= MoXaV2FPT0WU
OVCAR-8 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j2fWlEPTB;MUSuO|IxOSEQvF2= MmXJV2FPT0WU
NCI-H2347 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m5fWlEPTB;MUSuPFI{KM7:TR?= NHXhXXdUSU6JRWK=
BT-549 M1:3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K3RmlEPTB;MUSuPFI5PCEQvF2= MVvTRW5ITVJ?
LB831-BLC MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF2Lki5N|Qh|ryP NHjXTYpUSU6JRWK=
NCI-H661 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF2Lkm1PUDPxE1? M2izXHNCVkeHUh?=
MKN7 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF3LkCwPVMh|ryP NXzpO|JVW0GQR1XS
U-87-MG MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF3LkC4PVch|ryP Ml;oV2FPT0WU
OVCAR-4 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF3LkG0NlQh|ryP M1;TU3NCVkeHUh?=
OE33 NUjCWoF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF3LkG3NVEh|ryP NGOwXGtUSU6JRWK=
EC-GI-10 MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT5d5dKSzVyPUG1MlI{PTdizszN Mnf4V2FPT0WU
AM-38 M1j0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrxcHRqUUN3ME2xOU4zPzF5IN88US=> MlP4V2FPT0WU
NCI-H1563 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL4c5BlUUN3ME2xOU4{PDlizszN MnfSV2FPT0WU
SCC-4 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ZS3c{UUN3ME2xOU41OTB|IN88US=> MY\TRW5ITVJ?
Detroit562 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPzTWM2OD1zNT60OVQ4KM7:TR?= NFW2UYpUSU6JRWK=
PC-14 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELJZ2lKSzVyPUG1MlQ5PjZizszN NX\ZUJhMW0GQR1XS
ES3 NFvjeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;BdI1PUUN3ME2xOU42OzZizszN NWjNbHZOW0GQR1XS
OCI-AML2 NU[4d3Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomxTWM2OD1zNT63OlE1KM7:TR?= MnnjV2FPT0WU
LU-134-A MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF3LkmwNVgh|ryP NVLtfJBOW0GQR1XS
SAS MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF3LkmzO|Mh|ryP MmPZV2FPT0WU
TGBC11TKB NGfTU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr5WJJKSzVyPUG1Mlk1OTRizszN MnzpV2FPT0WU
HOP-62 M3X5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO0PHFKSzVyPUG1Mlk2QTdizszN M1jwUnNCVkeHUh?=
G-401 NIPKUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF3Lkm2OFkh|ryP MnuzV2FPT0WU
NCI-H28 NEHkWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTGVJU6UUN3ME2xOk4xQDV4IN88US=> MkW3V2FPT0WU
A204 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPiTWM2OD1zNj6yNFA3KM7:TR?= MnjiV2FPT0WU
NCI-H1299 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILmd41KSzVyPUG2MlIzQTFizszN M4S3XXNCVkeHUh?=
VMRC-RCZ MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rkTmlEPTB;MU[uNlU6OiEQvF2= NFOxeVBUSU6JRWK=
BxPC-3 M1PLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLoUopKSzVyPUG2MlI5PTZizszN NWK4OFFPW0GQR1XS
NCI-H2228 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jydmlEPTB;MU[uOVE2QCEQvF2= MmfyV2FPT0WU
NCI-H23 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rU[WlEPTB;MU[uOlA4QCEQvF2= MoTEV2FPT0WU
NKM-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmxTWM2OD1zNz6wNVg6KM7:TR?= NF7FN4FUSU6JRWK=
KYSE-70 NUDabWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nlZ2lEPTB;MUeuNlg6KM7:TR?= MniwV2FPT0WU
BB49-HNC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD4b5JKSzVyPUG3MlU3QDZizszN MY\TRW5ITVJ?
SCC-15 NUXLWlJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF5Lki0O|Mh|ryP M4XlVXNCVkeHUh?=
D-247MG NVLJUYdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P4NGlEPTB;MUeuPVI1PyEQvF2= Mo[zV2FPT0WU
BB30-HNC NYj5RZF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF6LkCzNVgh|ryP M3\NVHNCVkeHUh?=
CAL-85-1 MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnOTWFNUUN3ME2xPE4yQDB7IN88US=> MnruV2FPT0WU
HT-3 NGTVUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XGRWlEPTB;MUiuN|k4PyEQvF2= MnG3V2FPT0WU
KYSE-410 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF6LkS1O|ch|ryP MlrIV2FPT0WU
SW982 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF6LkW2OFkh|ryP MkXoV2FPT0WU
SW962 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Rb2lEPTB;MUiuOVcxOiEQvF2= M371bnNCVkeHUh?=
Ramos-2G6-4C10 NYLNSFFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jDbGlEPTB;MUiuOVkzPyEQvF2= M4THZXNCVkeHUh?=
OC-314 NEPVSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDrVFBKSzVyPUG4Mlc{QDRizszN MXXTRW5ITVJ?
LS-123 NIG5dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOyZlVKSzVyPUG4Mlc6ODFizszN M2DJV3NCVkeHUh?=
D-502MG M3niT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TRfmlEPTB;MUiuPFE{QSEQvF2= M{LrT3NCVkeHUh?=
RO82-W-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\2ZXVUUUN3ME2xPE45Ojh6IN88US=> MkfLV2FPT0WU
HuO9 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPNPFhvUUN3ME2xPU4yOzd7IN88US=> Mme0V2FPT0WU
ETK-1 NUfL[phZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF7LkG4Nlch|ryP MmrvV2FPT0WU
SNU-387 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDCTWM2OD1zOT6xPFg6KM7:TR?= M{f4WHNCVkeHUh?=
SW1573 NHPxOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nGfmlEPTB;MUmuNVk3QSEQvF2= M3XrNHNCVkeHUh?=
NTERA-S-cl-D1 NGTrNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDKTWM2OD1zOT6yNFA4KM7:TR?= MlzPV2FPT0WU
SF126 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDUTWM2OD1zOT6zOVAzKM7:TR?= NFXWUINUSU6JRWK=
Calu-3 NFTEfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3MTWM2OD1zOT60NlM4KM7:TR?= MV7TRW5ITVJ?
NCI-H1048 NW[xSlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPGS21KSzVyPUKwMlMzPjZizszN NXiyTZZuW0GQR1XS
NCI-H226 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPiSmdKSzVyPUKwMlQ{QTlizszN NF;ObpRUSU6JRWK=
FTC-133 M4GwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJyLkS3NFMh|ryP MlfCV2FPT0WU
SF539 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJyLkWxO|Ih|ryP MkjyV2FPT0WU
TE-6 M4r0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnXdI5mUUN3ME2yNE45ODZ5IN88US=> NEn3fIdUSU6JRWK=
UMC-11 NXS4dVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjvZ5dHUUN3ME2yNE46OTZ2IN88US=> M3fhb3NCVkeHUh?=
Becker NXHDfXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\FVIJKSzVyPUKxMlEyOThizszN MV;TRW5ITVJ?
KP-4 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTlWJRFUUN3ME2yNU4yOTl4IN88US=> MmPEV2FPT0WU
ChaGo-K-1 NUWwelYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDRTWM2OD1{MT6zOlI4KM7:TR?= NFv6O5lUSU6JRWK=
CFPAC-1 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDGTWM2OD1{MT6zPFU5KM7:TR?= M4DXenNCVkeHUh?=
A498 NEnTfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrjVppKSzVyPUKxMlU{OTJizszN NF7TTpZUSU6JRWK=
NCI-H1755 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJzLk[3OFEh|ryP NGj2WHNUSU6JRWK=
TI-73 NYXXT|N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL4ZpVKSzVyPUKyMlMzQCEQvF2= Ml\KV2FPT0WU
NCI-H441 M13FTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ{LkW2PFkh|ryP Mn;oV2FPT0WU
CaR-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvkPXNGUUN3ME2yN{4xOjF|IN88US=> M{jlfXNCVkeHUh?=
HCC1806 NXHzepJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonNTWM2OD1{Mz6wOVg{KM7:TR?= NVzZXllVW0GQR1XS
SNU-449 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj3TWM2OD1{Mz6zNlkh|ryP M4\aS3NCVkeHUh?=
EKVX MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DTcWlEPTB;MkOuN|kxQSEQvF2= M{HUPHNCVkeHUh?=
DMS-114 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjxc|lNUUN3ME2yN{42PzZ3IN88US=> MYPTRW5ITVJ?
A704 NWO5XIpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXnWJRKSzVyPUKzMlYyODNizszN NEXmWWtUSU6JRWK=
LC-2-ad M{XRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG0bmtjUUN3ME2yN{43OTR5IN88US=> M3ewVnNCVkeHUh?=
VM-CUB-1 NYfaTINQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXnRWFyUUN3ME2yN{44OzRzIN88US=> M4fyZnNCVkeHUh?=
PC-3 M1;RWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFftWJFKSzVyPUK0MlA2OjZizszN M3mxRnNCVkeHUh?=
HEL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;zTWM2OD1{ND6wPFY2KM7:TR?= M1HtUXNCVkeHUh?=
ABC-1 NXHvNnVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LvdmlEPTB;MkSuNlczQSEQvF2= M3jpNnNCVkeHUh?=
COLO-680N NVPscnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofNTWM2OD1{ND60O|Y1KM7:TR?= NEPnPY9USU6JRWK=
MZ1-PC NHfEWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\yVlVKSzVyPUK0MlY5PyEQvF2= MmXkV2FPT0WU
NCI-H69 M1;RWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXLTWM2OD1{ND63N|U1KM7:TR?= NYnvOG1jW0GQR1XS
TE-1 NX\ifGVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ3LkC0PVkh|ryP M3rlfnNCVkeHUh?=
EW-3 NFPUdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\P[GlEPTB;MkWuNVE{KM7:TR?= MnvHV2FPT0WU
PANC-08-13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn5fIo1UUN3ME2yOU45OTB|IN88US=> MW\TRW5ITVJ?
NMC-G1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHVR29SUUN3ME2yOk4xODh6IN88US=> MVPTRW5ITVJ?
BT-20 NWDkXWxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL4TWM2OD1{Nj60OVQ{KM7:TR?= NHfLcGtUSU6JRWK=
TGBC24TKB M1LFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TyOmlEPTB;Mk[uO|M{OSEQvF2= NYXNR3Z7W0GQR1XS
TE-11 NUjyNYpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorFTWM2OD1{Nj65PFk2KM7:TR?= NIXOcopUSU6JRWK=
ESS-1 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ5LkOyNVYh|ryP NYXY[nJVW0GQR1XS
JVM-3 NHG2blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ5Lk[0O|Uh|ryP NUWzVpdJW0GQR1XS
C3A M1\kSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHtZ2lKSzVyPUK3Mlg1QTZizszN NHm0[mFUSU6JRWK=
MDA-MB-157 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ5Lki3OVMh|ryP NGXCVIZUSU6JRWK=
KLE M{G5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ6LkGwOVgh|ryP MljTV2FPT0WU
ES1 M1nX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MleyTWM2OD1{OD6xPFM5KM7:TR?= MUfTRW5ITVJ?
CAL-120 M1vwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPPb2VGUUN3ME2yPE4{QTl7IN88US=> NWDNXJlTW0GQR1XS
NCI-N87 NVrpe3MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PBVWlEPTB;MkiuOVExPSEQvF2= NXvVW3ppW0GQR1XS
RPMI-8226 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHCfppSUUN3ME2yPU4yQDR|IN88US=> NYPoeWNEW0GQR1XS
COR-L88 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e3U2lEPTB;MkmuNlQyQSEQvF2= NHLrTJJUSU6JRWK=
UACC-893 M1XNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHSb45KSzVyPUK5MlMyOzdizszN MYjTRW5ITVJ?
C8166 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ7Lkm5PVYh|ryP Mk[0V2FPT0WU
J82 M2\oWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfrSldCUUN3ME2zNE45OTR5IN88US=> NVrzOIFHW0GQR1XS
PFSK-1 NWm4dHZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W5O2lEPTB;M{GuNFY2QSEQvF2= NF3Nem1USU6JRWK=
COLO-684 M2mzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTNzLkSzO|Qh|ryP M2m1Z3NCVkeHUh?=
CAL-72 NYfsTpdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLPTWM2OD1|MT61O|I6KM7:TR?= NYna[GdmW0GQR1XS
SNB75 NUfDSGF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq5TFFKSzVyPUOxMlg6PyEQvF2= NXnDZ2VYW0GQR1XS
MDA-MB-415 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrEbllKSzVyPUOxMlk4PjJizszN NE\ye2pUSU6JRWK=
SiHa M3;uWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf0bm97UUN3ME2zNk41PzFzIN88US=> Mlq5V2FPT0WU
NCI-H1648 M1Xmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Hb2pKSzVyPUOyMlk{PDVizszN MoTEV2FPT0WU
EFO-21 M2jaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nTNmlEPTB;M{OuNFA2KM7:TR?= NW[4d4FRW0GQR1XS
HCC38 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILzeYRKSzVyPUOzMlM5PDFizszN NHPJe5JUSU6JRWK=
IA-LM NIDVb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSxTWM2OD1|Mz63PFg6KM7:TR?= NWTQeWpEW0GQR1XS
CTV-1 M4nuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\IZ3UzUUN3ME2zN{46Pzh4IN88US=> MWXTRW5ITVJ?
NCI-H446 NWLhOYZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofBTWM2OD1|ND6yOlg6KM7:TR?= MYLTRW5ITVJ?
IST-SL1 NXjU[lVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr6TWM2OD1|ND63OFA5KM7:TR?= MoHxV2FPT0WU
EW-22 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN2Lke3OVkh|ryP NUPFT5FsW0GQR1XS
JEG-3 NX3Qd41wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjtTHMyUUN3ME2zOk4yPzZ4IN88US=> M1HUVnNCVkeHUh?=
LU-65 NEnLbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfvcmZxUUN3ME2zOk4zQTh3IN88US=> MkG1V2FPT0WU
NCI-H596 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q5WmlEPTB;M{[uPVU6OSEQvF2= MXvTRW5ITVJ?
KNS-81-FD NH7IbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXDTWM2OD1|Nz6xOFUh|ryP MUPTRW5ITVJ?
NCI-H1793 M1jGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vmZ2lEPTB;M{euO|A5PiEQvF2= M4rsbnNCVkeHUh?=
NCI-H460 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN6LkC4O|Mh|ryP NY\CNlR5W0GQR1XS
MPP-89 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzRbGQ2UUN3ME2zPU42QDh4IN88US=> NXO3bpRuW0GQR1XS
D-542MG NYjSeZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN7Lki0N|Yh|ryP Moj1V2FPT0WU
JAR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTRyLkS3NFUh|ryP Ml;3V2FPT0WU
NCI-H209 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\MTWM2OD12MD62O|ch|ryP NV3lV5VlW0GQR1XS
G-402 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHK[XdKSzVyPUSxMlM6QTNizszN M1HV[HNCVkeHUh?=
IST-MES1 NWrodZpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR{LkG5N|Uh|ryP NHruPFZUSU6JRWK=
Daoy MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HiWGlEPTB;NEKuOVQ4OSEQvF2= MYjTRW5ITVJ?
EW-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR|LkGyNVEh|ryP M{C3Z3NCVkeHUh?=
Saos-2 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rjU2lEPTB;NEOuNVU{PyEQvF2= Mkm3V2FPT0WU
no-10 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTR|LkG3NFIh|ryP MlrUV2FPT0WU
HCC1395 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\WRZdKSzVyPUSzMlQ3PDRizszN NHjEZY1USU6JRWK=
HCE-4 NWnaUXh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrmVnZKSzVyPUSzMlc3PjRizszN NYPkc4FWW0GQR1XS
EW-1 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HXdWlEPTB;NEOuPFA1QSEQvF2= MXXTRW5ITVJ?
OCUB-M NWLpNpVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTR2LkO2N|gh|ryP NIPyeHRUSU6JRWK=
IGR-1 M1riRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\RdWxKSzVyPUS0MlQyOTVizszN MX3TRW5ITVJ?
NCI-H1838 NGj3coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR2LkSzOFkh|ryP NHuzcndUSU6JRWK=
NCI-H2405 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTR2LkWzOEDPxE1? M4\HWHNCVkeHUh?=
GB-1 M1myc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS0SVlvUUN3ME20OE44PDZ|IN88US=> Mm\FV2FPT0WU
MG-63 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmWyTWM2OD12Nj6wOlk3KM7:TR?= NXzpfmk1W0GQR1XS
KP-N-YN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP5W2pKSzVyPUS2MlQ3PzlizszN M3PHV3NCVkeHUh?=
no-11 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTR5LkCyOFQh|ryP MYPTRW5ITVJ?
SW948 NHPCZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR5LkOzO|ch|ryP NFX6R2NUSU6JRWK=
CAMA-1 M1TEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTR5LkO0N|gh|ryP NVfneVg5W0GQR1XS
HCC1187 NIKxbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vpT2lEPTB;NEeuOVEh|ryP MnHrV2FPT0WU
D-392MG MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnTd4lpUUN3ME20O{43PTF4IN88US=> NH70PY5USU6JRWK=
647-V MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrQNpBKSzVyPUS5MlM1OTRizszN NF3Xd3lUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water slightly soluble or insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID